Intracellular activity of a membrane-active glycopeptide antibiotic against meticillin-resistant Staphylococcus aureus infection

J Glob Antimicrob Resist. 2016 Jun:5:71-4. doi: 10.1016/j.jgar.2015.12.007. Epub 2016 Jan 19.

Abstract

Staphylococcus aureus is a facultative intracellular pathogen and there are limited options for the treatment of severe intracellular bacterial infections. The membrane-active glycopeptide antibiotic Van-QC8 is a permanent positively charged lipophilic vancomycin analogue that demonstrates high activity against clinically relevant drug-resistant Gram-positive bacteria both in vitro and in vivo. In this study, the intracellular activity of Van-QC8 was evaluated against meticillin-resistant S. aureus (MRSA) infection in RAW macrophages. Furthermore, the mechanism of intracellular uptake of Van-QC8 was investigated. Van-QC8 showed time- and concentration-dependent bactericidal activity against intracellular MRSA. Van-QC8 displayed significantly higher intracellular activity compared with vancomycin and linezolid. Cellular uptake of Van-QC8 was found to be through clathrin-dependent and -independent and caveolin-dependent and -independent endocytic pathways. The findings of this study suggest that Van-QC8 could be translated clinically for the treatment of intracellular infections due to MRSA.

Keywords: Glycopeptides; Intracellular activity; MRSA; Membrane-active antibiotic; Meticillin-resistant Staphylococcus aureus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Glycopeptides / pharmacology*
  • Methicillin-Resistant Staphylococcus aureus / drug effects*
  • Mice
  • RAW 264.7 Cells
  • Vancomycin / analogs & derivatives*

Substances

  • Anti-Bacterial Agents
  • Glycopeptides
  • Vancomycin